Safety and efficacy of preoperative chemotherapy with mFOLFOX6+Bevacizumab in patients with liver-only metastases (H2, H3) from colorectal cancer; histological assessment of liver damage from preoperative chemotherapy.
Ontology highlight
ABSTRACT: Interventions: mFOLFOX6+Bevacizumab was administered for six cycles, but sixth cycle of therapy did not include Bevacizumab. Surgery was planned 2 weeks after the last dose of chemotherapy, resulting in a gap of 6-9 weeks between surgery and the last Bevacizumab dose.
Primary outcome(s): Liver resection rate
Study Design: Single arm Non-randomized
DISEASE(S): Patients With Liver-only Metastases From Colorectal Cancer
PROVIDER: 2616801 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA